Similar articles

• New trends in the endocrine treatment of breast cancer.

  Maass H, Jonat W, Eidtmann H, Kunz T, Kügler G. Maass H, et al. Recent Results Cancer Res. 1990;118:225-32. doi: 10.1007/978-3-642-83816-3_21. Recent Results Cancer Res. 1990. PMID: 2146726 Review. No abstract available.
• Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-I levels in breast cancer patients.

  Lien EA, Johannessen DC, Aakvaag A, Lønning PE. Lien EA, et al. J Steroid Biochem Mol Biol. 1992 Mar;41(3-8):541-3. doi: 10.1016/0960-0760(92)90380-2. J Steroid Biochem Mol Biol. 1992. PMID: 1532904
• Aromatase inhibitors in the treatment of advanced breast cancer.

  Miller WR. Miller WR. Cancer Treat Rev. 1989 Jun;16(2):83-93. doi: 10.1016/0305-7372(89)90012-1. Cancer Treat Rev. 1989. PMID: 2527597 Review. No abstract available.
• Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer.

  Anderson ED, Forrest AP, Levack PA, Chetty U, Hawkins RA. Anderson ED, et al. Br J Cancer. 1989 Aug;60(2):223-6. doi: 10.1038/bjc.1989.256. Br J Cancer. 1989. PMID: 2527549 Free PMC article.
• Primary systemic therapy for operable breast cancer.

  Anderson ED, Forrest AP, Hawkins RA, Anderson TJ, Leonard RC, Chetty U. Anderson ED, et al. Br J Cancer. 1991 Apr;63(4):561-6. doi: 10.1038/bjc.1991.131. Br J Cancer. 1991. PMID: 1827031 Free PMC article. Clinical Trial.